ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27.
Saved in:
| Title: | ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27. |
|---|---|
| Authors: | Wang Y; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Wang Y; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Bao L; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Vale G; Center for Human Nutrition, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, TX, USA., McDonald JG; Center for Human Nutrition, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, TX, USA., Fang Y; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Peng Y; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Kumar A; Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX, USA., Xing C; Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX, USA.; Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Diseases, Hospital Clínic of Barcelona, Barcelona, Spain.; Reveal Genomics, S.L., Barcelona, Spain., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Diseases, Hospital Clínic of Barcelona, Barcelona, Spain.; Reveal Genomics, S.L., Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Institute of Oncology-Hospital Quirónsalud, Barcelona, Spain., Arteaga CL; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Wang Y; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.; Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.; Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA., Luo W; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA. Weibo.Luo@UTSouthwestern.edu.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Weibo.Luo@UTSouthwestern.edu.; Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX, USA. Weibo.Luo@UTSouthwestern.edu. |
| Source: | Nature communications [Nat Commun] 2025 Apr 25; Vol. 16 (1), pp. 3908. Date of Electronic Publication: 2025 Apr 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
